Risperidone, but Not Olanzapine, Decreases Bone Mineral Density in Female Premenopausal Schizophrenia Patients
J Clin Psychiatry 2003;64(7):761-766
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The hyperprolactinemia
induced by conventional antipsychotics often leads to
osteoporosis. The commonly used atypical antipsychotics
risperidone and olanzapine vary in their hyperprolactinemic
properties. Therefore, we compared hormone profiles and bone
properties in female premenopausal schizophrenia patients treated
with either risperidone or olanzapine.
Method: In a cross-sectional study,
consecutive premenopausal, female, DSM-IV schizophrenia patients
who were treated with either risperidone (N = 12) or olanzapine
(N = 14) for at least 2 years were included. Dual energy X-ray
absorptiometry evaluated bone mineral density, and multisite
quantitative ultrasound measured bone speed of sound. In
addition, profiles of urinary excretion of deoxypyridinoline and
circulating levels of hormones and lipids were assessed.
Results: Serum prolactin levels were
higher in the risperidone-treated group as compared with the
olanzapine subjects (123 ± 144 and 25.9 ± 25.7, p < .05).
Whereas bone mineral density was similar in the treatment groups,
bone speed of sound was lower in the risperidone group as
compared with the olanzapine-treated group. Expressed as
age-adjusted Z score, bone speed of sound at the radius was -0.31
and 0.58, respectively, p < .05, and at the phalanx, -1.41 and
0.04, respectively, p < .05. The bone speed of sound in the
risperidone-treated patients inversely correlated with urinary
deoxypyridinoline excretion (r = 0.73, p < .05).
Conclusion: Risperidone treatment, as
opposed to olanzapine, for female premenopausal schizophrenia
results in hyperprolactinemia and clinically relevant decrease in
bone mineral density. The calculated relative risk for fragility
fracture of women treated with risperidone as compared to those
treated with olanzapine is 1.78 when bone speed of sound was
measured at the phalanx and 1.23 when measured at the radius.